Findings

What do systematic reviews say?

6 questions · 6 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 16.7%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 33.3%Moderate 3 · 50%High 0 · 0%

Oral miltefosine (50 mg for 28 days) vs 28 days on/off placebo regimen

Complete cure, at least 3 months after the end of treatment · People with American cutaneous and mucocutaneous leishmaniasis

Oral miltefosine (50 mg for 28 days) probably leads to higher complete cure, at least 3 months after the end of treatment compared with placebo (same regimen) (moderate certainty).

1 finding from 1 review

Interventions for American cutaneous and mucocutaneous leishmaniasis 2020 · Cochrane Headline outcomes only
RR 2.25 [1.42, 3.38]
1 study · 133 participants
Moderate

Oral miltefosine (50 mg for 28 days) vs 28 days on/off placebo regimen

Adverse effects (number of participants who had the event) · People with American cutaneous and mucocutaneous leishmaniasis

Oral miltefosine (50 mg for 28 days) probably leads to higher adverse effects (number of participants who had the event) compared with placebo (same regimen) (moderate certainty).

1 finding from 1 review

Interventions for American cutaneous and mucocutaneous leishmaniasis 2020 · Cochrane Headline outcomes only
RR 3.96 [1.49, 10.48]
1 study · 133 participants
Moderate

Oral miltefosine (50 mg for 28 days) vs 28 days on/off placebo regimen

Recurrence · People with American cutaneous and mucocutaneous leishmaniasis

Oral miltefosine (50 mg for 28 days) showed no clear difference in recurrence compared with placebo (same regimen) (low certainty).

1 finding from 1 review

Interventions for American cutaneous and mucocutaneous leishmaniasis 2020 · Cochrane Headline outcomes only
RR 2.97 [0.37, 23.89]
1 study · 133 participants
Low

Oral miltefosine (1.2 to 3.3 mg/kg/d 28 days) vs meglumine antimoniate (20 mg/kg 20 days)

Complete cure, at least 3 months after the end of treatment · People with American cutaneous and mucocutaneous leishmaniasis

Oral miltefosine (1.2 to 3.3 mg/kg/d 28 days) showed no clear difference in complete cure, at least 3 months after the end of treatment compared with meglumine antimoniate (20 mg/kg 20 days) (low certainty).

1 finding from 1 review

Interventions for American cutaneous and mucocutaneous leishmaniasis 2020 · Cochrane Headline outcomes only
RR 1.05 [0.9, 1.23]
7 studies · 676 participants
Low

Oral miltefosine (1.2 to 3.3 mg/kg/d 28 days) vs meglumine antimoniate (20 mg/kg 20 days)

Adverse effects (number of participants who had the event) · People with American cutaneous and mucocutaneous leishmaniasis

Oral miltefosine (1.2 to 3.3 mg/kg/d 28 days) probably leads to higher adverse effects (number of participants who had the event) compared with meglumine antimoniate (20 mg/kg 20 days) (moderate certainty).

1 finding from 1 review

Interventions for American cutaneous and mucocutaneous leishmaniasis 2020 · Cochrane Headline outcomes only
RR 2.45 [1.72, 3.49]
3 studies · 464 participants
Moderate

Oral miltefosine (1.2 to 3.3 mg/kg/d 28 days) vs meglumine antimoniate (20 mg/kg 20 days)

Recurrence ‐ not measured · People with American cutaneous and mucocutaneous leishmaniasis

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for American cutaneous and mucocutaneous leishmaniasis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found